Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | ACACB | O00763 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ACACA | Q13085 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9885074 | 1.00 | KMT2A (0.54) | KMT2ADRD2ACACBMEN1ALDH1A1 | |
| SCHEMBL4377073 | 0.88 | KMT2A (0.56) | KMT2ADRD2ACACBACACAEPHX1 | |
| SCHEMBL190838 | 0.88 | KMT2A (0.56) | KMT2ADRD2ACACBACACAEPHX1 | |
| SCHEMBL3816616 | 0.88 | KMT2A (0.56) | KMT2ADRD2ACACBACACAEPHX1 | |
| SCHEMBL3942686 | 0.88 | KMT2A (0.56) | KMT2ADRD2ACACBACACAEPHX1 | |
| SCHEMBL14979024 | 0.86 | KMT2A (0.56) | KMT2ADRD2ACACBACACASMN1; SMN2 | |
| SCHEMBL353652 | 0.86 | KMT2A (0.71) | KMT2ADRD2ACACBACACASMN1; SMN2 | |
| SCHEMBL353639 | 0.86 | KMT2A (0.71) | KMT2ADRD2ACACBACACASMN1; SMN2 | |
| SCHEMBL10163711 | 0.86 | KMT2A (0.56) | KMT2ADRD2ACACBACACASMN1; SMN2 | |
| SCHEMBL5006161 | 0.86 | KMT2A (0.71) | KMT2ADRD2ACACBACACASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022212902-A1 | MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAY | ALTOS LABS, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2020135765-A1 | CXCR4 INHIBITOR AND APPLICATION THEREOF | 珠海诺贝尔国际生物医药研究院有限公司 | 2020-07-02 | — | — | WO | disclosed |
| US-10562977-B2 | Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2020-02-18 | — | — | US | disclosed |
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-25 | — | — | US | disclosed |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20110245223-A1 | HETEROCYCLIC COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2011-10-06 | — | — | US | disclosed |
| US-20100010219-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-7589197-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY (TW) | 2009-09-15 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| EP-1031563-B1 | SULFONYL DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| US-20030232808-A1 | Sulfonyl derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-12-18 | — | — | US | disclosed |
| US-6525042-B1 | Inhibits an activated coagulation factor FXa; anticoagulant, antithrombotic | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-02-25 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
| EP-1031563-A1 | SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | KMT2A 3061/4885DRD2 214/4885ACACB 3946/4885 |
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | NR3C2, REN, NR5A1 | KMT2A 2546/4885DRD2 3096/4885ACACB 2125/4885 |
| US-20110245223-A1 | HETEROCYCLIC COMPOUNDS | HSD11B1, HSD11B2, CYP11B1 | KMT2A 1820/4885DRD2 241/4885ACACB 2490/4885 |
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | NR3C2, REN, CYP21A2 | KMT2A 2905/4885DRD2 3269/4885ACACB 2138/4885 |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | KMT2A 923/4885DRD2 797/4885ACACB 1694/4885 |
| US-20100010219-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | HSD11B1, HSD11B2, HSD17B11 | KMT2A 3033/4885DRD2 1276/4885ACACB 1551/4885 |
| US-20030232808-A1 | Sulfonyl derivatives | SULT1E1, SULT2A1, SULT1A1 | KMT2A 479/4885DRD2 855/4885ACACB 3919/4885 |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | NR3C2, REN, NR5A1 | KMT2A 2546/4885DRD2 3096/4885ACACB 2125/4885 |
| US-10562977-B2 | Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof | LPXN, ADGRF1, LHCGR | KMT2A 2850/4885DRD2 670/4885ACACB 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.